

AMENDMENTS TO THE CLAIMS:

The following listing of claims replaces all prior versions or listings of claims in the application. Claims 1-8 are hereby canceled.

Listing of Claims:

Claims 1-8 (canceled)

Claim 9 (new): A method for detecting the presence of human papillomavirus in a sample comprising:

combining a test sample containing sample nucleic acids with a composition comprising at least one nucleotide sequence from human papillomavirus-33; and  
identifying the presence of hybrids formed between said sample nucleic acids and said at least one nucleotide sequence from human papillomavirus-33.

Claim 10 (new): The method according to claim 9, wherein the at least one nucleotide from human papillomavirus-33 is labeled.

Claim 11 (new): The method according to claim 10, wherein the at least one nucleotide from human papillomavirus-33 is labeled with at least one of an enzyme, a radioactive compound, and a fluorescent compound.

Claim 12 (new): The method according to claim 9, wherein the identifying the presence of hybrids is performed enzymatically, radioactively, or fluorescently.

Claim 13 (new): The method of claim 9, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises a complete human papillomavirus-33 DNA sequence.

Claim 14 (new): The method of claim 9, wherein the at least one nucleotide sequence from human papillomavirus-33 comprises a fragment of a human papillomavirus-33 DNA sequence.

Claim 15 (new): The process of claim 14, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in Figures 1a and 1b: a) 76-556, b) 543-864, c) 867-2811, d) 2728-3808, e) 3326-3575, f) 3842-4079, g) 4198-5611, and h) 5516-7091.

Claim 16 (new): The process of claim 15, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in Figures 1a and 1b: a) 4198-5611, and b) 5516-7091.

Claim 17 (new): The process of claim 14, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in Figures 1a and 1b: a) 109-556, b) 573-864, c) 879-2811, d) 2749-3808, e) 3326-3575, f) 3842-4079, g) 4210-5611 and h) 5594-7091.

**Claim 18 (new):** The process of claim 17, wherein said fragment comprises at least one nucleotide sequence selected from the following group of nucleotide sequences numbered as shown in Figures 1a and 1b: a) 4210-5611 and b) 5594-7091.

**Claim 19 (new):** The process of claim 14, wherein said fragment comprises a 78-base sequence identified as 78-1 in Figure 3.

**Claim 20 (new):** The process of claim 14, wherein said fragment comprises a 156- base sequence identified as 78-1 and 78-2 in Figure 3.

**Claim 21 (new):** The process of claim 14, wherein said fragment comprises a nucleotide sequence extending from nucleotide 229 to nucleotide 404 of Figure 1a.